Oncology Institute (NASDAQ:TOI) Director Mohit Kaushal Sells 38,433 Shares

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Mohit Kaushal sold 38,433 shares of the business's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $3.50, for a total value of $134,515.50. Following the completion of the sale, the director directly owned 172,583 shares of the company's stock, valued at approximately $604,040.50. This represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mohit Kaushal also recently made the following trade(s):

• On Tuesday, April 14th, Mohit Kaushal sold 57,286 shares of Oncology Institute stock. The shares were sold at an average price of $3.50, for a total value of $200,501.00.

Oncology Institute Stock Up 3.2%

Shares of Oncology Institute stock opened at $3.54 on Friday. The firm has a market cap of $349.89 million, a P/E ratio of -6.32 and a beta of 0.17. The Oncology Institute, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $4.88. The business has a 50-day moving average price of $2.95 and a 200 day moving average price of $3.38.

---

---

Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $141.96 million during the quarter, compared to the consensus estimate of $139.78 million.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TOI shares. Weiss Ratings restated a "sell (d-)" rating on shares of Oncology Institute in a research note on Wednesday, January 21st. B. Riley Financial lifted their target price on Oncology Institute from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, March 13th. Needham & Company LLC restated a "buy" rating and issued a $5.00 target price on shares of Oncology Institute in a research note on Monday, March 9th. Finally, BTIG Research restated a "buy" rating and issued a $7.00 target price on shares of Oncology Institute in a research note on Monday, March 9th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $7.00.

Check Out Our Latest Research Report on Oncology Institute

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds and other institutional investors have recently bought and sold shares of TOI. Kestra Advisory Services LLC acquired a new position in Oncology Institute in the fourth quarter valued at approximately $31,000. Pekin Hardy Strauss Inc. acquired a new position in shares of Oncology Institute during the fourth quarter worth approximately $36,000. Cetera Investment Advisers boosted its position in shares of Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock worth $36,000 after buying an additional 4,545 shares during the period. State of Wyoming acquired a new position in shares of Oncology Institute during the second quarter worth approximately $37,000. Finally, R Squared Ltd acquired a new position in shares of Oncology Institute during the fourth quarter worth approximately $41,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Company Profile

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.

Read More

• Five stocks we like better than Oncology Institute

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].